IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).

出版年份 2016 全文链接

标题

作者

关键词

出版物

Volume 34, Issue 2_suppl, Pages 355-355

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2017-02-24

DOI

10.1200/jco.2016.34.2_suppl.355

Discuss science. Find collaborators. Network.

Join a conversation

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started